Results 221 to 230 of about 235,574 (356)

Expression of major histocompatibility complex class I antigens as a strategy for the potentiation of immune recognition of tumor cells. [PDF]

, 1986
Karo Tanaka, Hiroaki Hayashi, Chieko Hamada, George Khoury, Gregory D. Jay   +4 more
openalex   +1 more source

Twenty‐year survival outcomes after multipeptide vaccination for resected high‐risk melanoma: A post‐hoc analysis of a randomized clinical trial

International Journal of Cancer, EarlyView.
What's New? While melanoma vaccines have shown therapeutic promise, predicting their clinical benefits is challenged by factors such as delayed response to immunotherapy and scarcity of biomarkers. Here, the authors examined the long‐term efficacy of vaccination with either 4 or 12 class I MHC‐restricted peptides in high‐risk melanoma.
Emily K. Ninmer, Hong Zhu, Kimberly A. Chianese‐Bullock, Craig L. Slingluff Jr.   +3 more
wiley   +1 more source

Unraveling the architecture of major histocompatibility complex class II haplotypes in rhesus macaques. [PDF]

Genome Res
de Groot N, van der Wiel M, Le NG, de Groot NG, Bruijnesteijn J, Bontrop RE.   +5 more
europepmc   +1 more source

Specific, major histocompatibility complex-unrestricted recognition of tumor-associated mucins by human cytotoxic T cells.

, 1989
Donna L. Barnd, Michael S. Lan, Richard S. Metzgar, Olivera J. Finn   +3 more
openalex   +1 more source

Developmental and tissue-specific expression of nuclear proteins that bind the regulatory element of the major histocompatibility complex class I gene. [PDF]

, 1989
Peter Burke, Steven Hirschfeld, Yasuaki Shirayoshi, John W. Kasik, Keisuke Hamada, Ettore Appella, Keiko Ozato   +6 more
openalex   +1 more source

CD86, the double agent: Significance of CD86 expression in B‐cell malignancies

International Journal of Cancer, EarlyView.
Abstract Bypassing the anti‐tumor functions of the immune system is one of the keys to tumor survival. Tumors, especially hematological tumors, produce or express factors that retune T and B cells to inhibit the immune response. Coreceptors CD28 and CTLA‐4, and their ligands, CD80 and CD86, are involved in the immunological synapse and play an ...
Gábor Barna, Gábor Szalóki, Ágnes Márk, Anna Hunyadi, Csilla Kriston   +4 more
wiley   +1 more source

Correction to: PIPLOM: prediction of exogenous peptide loading on major histocompatibility complex class I molecules. [PDF]

Bioinform Adv
europepmc   +1 more source

Palaeognaths Reveal Evolutionary Ancestry of the Avian Major Histocompatibility Complex Class II. [PDF]

Genome Biol Evol
Minias P, Babik W.
europepmc   +1 more source

Targeting aerobic glycolysis combats tyrosine kinase inhibitor resistance of hepatocellular carcinoma

International Journal of Cancer, EarlyView.
Abstract Hepatocellular carcinoma (HCC) represents the predominant form of primary liver cancer and is frequently identified at a late stage, necessitating systemic therapy. However, resistance to first‐line tyrosine kinase inhibitor therapies, such as sorafenib and lenvatinib, remains a significant clinical challenge.
Longtao Zhao, Junjie Cheng, Yiming Zheng, Jing Wu, Jia Fan, Haixiang Sun, Chao Gao   +6 more
wiley   +1 more source

The role of major histocompatibility complex molecules in luteal function

Reproductive Biology and Endocrinology, 2003
Pate Joy L, Cannon Matthew J
doaj   +1 more source